View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBellicum Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Bellicum Pharmaceuticals은 연평균 44.5%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 0.8%의 비율로 감소했습니다.핵심 정보44.47%순이익 성장률64.28%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률-0.79%자기자본이익률-486.06%순이익률-1,483.95%최근 순이익 업데이트30 Sep 2023최근 과거 실적 업데이트Reported Earnings • Apr 01Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.공시 • Mar 31Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020Bellicum Pharmaceuticals, Inc. reported impairment for the fourth quarter ended December 31, 2020. For the quarter, Impairment of property and equipment was $1,265,000.공시 • Sep 29Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019Bellicum Pharmaceuticals, Inc. announced that they will report Q4, 2018 results at 9:01 PM, GMT Standard Time on Mar 12, 2019모든 업데이트 보기Recent updates공시 • Mar 04Bellicum Pharmaceuticals Files Form 15Bellicum Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.공시 • Feb 22The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).The University of Texas M. D. Anderson Cancer Center agreed to acquire substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) for $8.1 million on November 21, 2023. Pursuant to the asset purchase agreement, MDACC will pay to Bellicum an amount equal to $8.1 million in cash and will assume certain related liabilities. The transaction is subject to receive approval from Bellicum’s stockholders and certain other customary closing conditions. The asset purchase agreement has been approved by the board of directors of Bellicum and The Board of Regents of the University of Texas System (the “UT Board of Regents”), the governing body for the University of Texas System. Matthew Browne, Rowook Park and Matthew Silverman of Cooley LLP acted as legal advisors to Bellicum Pharmaceuticals. Roger J. Griesmeyer of Katten Muchin Rosenman LLP acted as legal advisors to The University of Texas M.D. Anderson Cancer Center.The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) on February 21, 2024. As of January 29, 2024, the transaction has been approved by the shareholders of Bellicum Pharmaceuticals.공시 • Jul 08Nasdaq to Delist the Common Stock of Bellicum PharmaceuticalsNasdaq announced on July 6, 2023 that it will delist the common stock of Bellicum Pharmaceuticals, Inc. The company’s securities were suspended on June 2, 2023, and have not traded on Nasdaq since that time.공시 • Jun 03Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite IndexBellicum Pharmaceuticals, Inc. has been dropped from NASDAQ Composite Index.공시 • May 31Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)As previously disclosed by Bellicum Pharmaceuticals, Inc., pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol “BLCM".Major Estimate Revision • May 21Consensus EPS estimates fall by 39%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.49 to -US$0.68 per share. Revenue forecast of US$8.0k unchanged since last update. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$5.00 unchanged from last update. Share price rose 5.8% to US$0.79 over the past week.공시 • Feb 17Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers SymposiumBellicum Pharmaceuticals, Inc. will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients. These initial data from 2 cohorts consisted of 8 patients who received lympodepleting chemotherapy (fludarabine + cyclophosphamide) followed by a single dose of 5x106 BPX-601 cells/kg and single (n=3) or weekly (n=5) doses of 0.4 mg/kg rimiducid beginning 7 days following the cell infusion. GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40. The trial continues to enroll patients. The next cohorts in the Phase 1 trial will explore higher doses of rimiducid, which in non-clinical studies have been shown to increase GoCAR-T persistence, enhance pro-inflammatory cytokine production, and improve anti-tumor efficacy.공시 • Dec 12Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with RimiducidBellicum Pharmaceuticals, Inc. announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial. The poster titled “Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)” will also be available on Bellicum’s website. The UNC Lineberger research team reported the clinical and pharmacodynamic courses of ICANS for four patients treated with rimiducid in an ongoing cell dose expansion cohort of a Phase I/II trial of iC9 CAR.19 cells to treat B-lymphoblastic leukemia (B-ALL). According to the poster, rimiducid administration to these patients experiencing corticosteroid-unresponsive grade 3-4 ICANS was associated with abrupt reduction of circulating iC9 CAR.19 cells and lower ICANS grade within 24 hours. The UNC Lineberger research team concluded that iC9 holds promise as a tool to potentially abrogate the most severe CAR T-cell toxicities. The UNC Lineberger team is exploring lower doses of rimiducid to determine if—by preserving a higher percentage of CAR-T cells—toxicity may be mitigated without diminishing the therapeutic benefit.Price Target Changed • Nov 16Price target decreased to US$5.00Down from US$17.33, the current price target is provided by 1 analyst. New target price is 367% above last closing price of US$1.07. Stock is down 48% over the past year. The company is forecast to post a net loss per share of US$1.68 next year compared to a net loss per share of US$0.84 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Aug 11Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56Bellicum Pharmaceuticals press release (NASDAQ:BLCM): Q2 GAAP EPS of -$0.13 beats by $0.56. Cash and cash equivalents and restricted cash totaling $34.7M as of June 30, 2022. “We have continued to make progress with our patient enrollment efforts in the BPX-601 and BPX-603 trials and I am pleased with our execution,” said Rick Fair, President and Chief Executive Officer. “Our team remains focused on generating Phase 1 data that highlight the potential advantages of our GoCAR-T technology.”공시 • May 02Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022, at 13:00 Pacific Standard Time. Agenda: To elect one Class II director named herein to hold office until the 2025 Annual Meeting of Stockholders; to approve an amendment to the Company’s 2019 Equity Incentive Plan to, among other things, increase the number of shares of common stock authorized for issuance under the 2019 Plan by 2,250,000 shares; to ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors to serve as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement; and to consider other matters if any.Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$17.33, the current price target is provided by 1 analyst. New target price is 202% above last closing price of US$1.66. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$2.82 next year compared to a net loss per share of US$0.84 last year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$1.80, the stock trades at a trailing P/E ratio of 2.3x. Average forward P/E is 8x in the Biotechs industry in the US. Total loss to shareholders of 94% over the past three years.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improved over the past weekAfter last week's 34% share price gain to US$1.90, the stock trades at a trailing P/E ratio of 2.4x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 94% over the past three years.공시 • Feb 16Bellicum Pharmaceuticals, Inc. Announces Board ChangesOn February 14, 2022, James F. Brown notified Bellicum Pharmaceuticals, Inc. (the “Company”) of his resignation from his position as a member of the Company’s Board of Directors (the “Board”), including each committee of the Board on which he is a member, to be effective as of immediately prior to the Company’s 2022 annual meeting of stockholders. Effective as of Mr. Brown’s resignation, Jon P. Stonehouse will serve as interim Chairman of the Board.공시 • Dec 15Bellicum Regains Compliance with Nasdaq Continued Listing RequirementsBellicum Pharmaceuticals, Inc. announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the company’s recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.72, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 27x in the Biotechs industry in the US. Total loss to shareholders of 96% over the past three years.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$2.26, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.00, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 25x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years.Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$3.32, the stock trades at a trailing P/E ratio of 6.2x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years.공시 • May 19Bellicum Pharmaceuticals, Inc. Provides an Operational UpdateBellicum Pharmaceuticals, Inc. provided an operational update. BPX-601 GoCAR-T® •Patient enrollment is ongoing in the Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. •Bellicum plans to present a Phase 1 data update on BPX-601 and rimiducid in patients with metastatic castration-resistant prostate cancer in the first quarter of 2022. BPX-603 GoCAR-T•Bellicum is conducting its Phase 1/2 clinical trial for BPX-603 in patients with solid tumors that express human epidermal growth factor 2 (HER2), including breast, endometrial, ovarian, gastric, and colorectal cancers. BPX-603 is the company’s first dual-switch GoCAR-T product candidate, which incorporates Bellicum’s iMC activation and CaspaCIDe® safety switch technologies. The company expects to present initial Phase 1 data from this trial in the fourth quarter of 2021. CaspaCIDe •As announced in February, the first reported use of the CaspaCIDe safety switch to mitigate CAR-T cell toxicity was published as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. The report described a case from an investigator-sponsored trial at the University of North Carolina Lineberger Comprehensive Cancer Center of autologous CAR-T cells expressing CD19 and CaspaCIDe. In this patient, grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) refractory to standard therapies was treated with rimiducid to activate CaspaCIDe. Within 12 hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days.Reported Earnings • Apr 01Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.공시 • Mar 31Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020Bellicum Pharmaceuticals, Inc. reported impairment for the fourth quarter ended December 31, 2020. For the quarter, Impairment of property and equipment was $1,265,000.공시 • Mar 06Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell ToxicityBellicum Pharmaceuticals, Inc. announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch. The letter to the editor titled “Utility of Safety Switch to Abrogate CD 19 CAR T Cell-Associated Neurotoxicity” appeared as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. Link to article. The publication detailed a case report from an investigator-sponsored trial (IST) at the University of North Carolina Lineberger Comprehensive Cancer Center, where a Phase 1/2 trial is ongoing to test the safety and efficacy of autologous T lymphocytes genetically modified to express a CD19 chimeric antigen receptor (CAR) and iC9. A patient in the dose expansion cohort of this trial experienced a high grade neurologic adverse event with persistence of grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) for 72 hours despite standard care, and rimiducid was subsequently given per protocol to activate iC9. Within twelve hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days. This publication marked the first reported clinical use of the iC9 safety switch to mitigate a severe CAR-T-mediated adverse event refractory to standard of care treatment.Is New 90 Day High Low • Jan 30New 90-day high: US$4.65The company is up 25% from its price of US$3.71 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 25% over the same period.Price Target Changed • Jan 30Price target lowered to US$4.50Down from US$17.33, the current price target is an average from 2 analysts. The new target price is close to the current share price of US$4.65. As of last close, the stock is down 62% over the past year.공시 • Jan 29Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical TrialBellicum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. Bellicum worked diligently with the FDA over the past two months to respond to the clinical hold and has been informed by FDA that the company has satisfactorily addressed all clinical hold issues. Bellicum may now resume enrollment without modification to the current study protocol. The company plans to work with clinical investigators to resume patient enrollment. About BPX-601: BPX-601, the company’s first GoCAR-T product candidate, incorporates iMC, Bellicum’s inducible co-activation domain. iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence, production of immunomodulatory cytokines and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA).공시 • Jan 28Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic IndexBellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index공시 • Jan 12Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021On January 5, 2021, David Strauss notified Bellicum Pharmaceuticals, Inc. of his resignation from his position as the Company’s Senior Director, Corporate Controller, and as the Company’s principal accounting officer, to be effective January 22, 2021.공시 • Dec 12Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603Bellicum Pharmaceuticals, Inc. announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T® product candidate that incorporates the company’s iMC activation and CaspaCIDe® safety switch technologies. This Phase 1/2, open-label, multicenter, non-randomized study will investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid. The trial will enroll patients with previously treated, locally advanced or metastatic solid tumors with HER2 amplification or overexpression. The initial dose escalation phase of the trial is designed to evaluate safety and identify the Phase 2 dose of BPX-603 administered with rimiducid at a fixed dose of 0.4 mg/kg per infusion. The Phase 2 portion of the trial will assess the safety, pharmacodynamics, and clinical activity of BPX-603 in various HER2+ solid tumors. Tumor types that may be studied include gastric, breast, ovarian, endometrial, and colorectal.공시 • Dec 10Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical TrialBellicum Pharmaceuticals, Inc. announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer. The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid. The company plans to work diligently with the FDA to address the agency’s questions and fulfill the requirements for resuming the trial. The clinical hold does not affect the company’s plans to initiate enrollment in the Phase 1/2 clinical trial of BPX-603, a dual switch GoCAR-T®, in patients with HER2+ solid tumors by the end of the year.공시 • Oct 30Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020Bellicum Pharmaceuticals, Inc. staff will be reduced by 79%, from 68 to 14 full-time employees by the end of 2020.공시 • Sep 29Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019Bellicum Pharmaceuticals, Inc. announced that they will report Q4, 2018 results at 9:01 PM, GMT Standard Time on Mar 12, 2019공시 • Jul 31The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).The University of Texas MD Anderson Cancer Center entered into an asset purchase agreement to acquire certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) for $15 million on January 17, 2020. The purchase price of $15 million is payable in cash upon closing, less $1.5 million to be held in escrow for up to 18 months after the closing of the transaction. Under the transaction, The University of Texas MD Anderson Cancer Center will acquire approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space. Approximately 35 employees currently employed at the facility will be employed by MD Anderson. The transaction is subject to approval of the Board of Regents of the University of Texas System, the entry into a master services agreement between Bellicum and The University of Texas MD Anderson Cancer Center, completion of an on-site inspection of the facility by certain regulatory entities, Bellicum obtaining consent from the landlord of the facility, and the satisfaction of customary terms and conditions, including adjustment to the purchase price. The transaction is expected to close on or before February 21, 2020. As of March 12, 2020, the closing of the transaction is expected to occur on or before March 31, 2020. Andrew L. Strong of Pillsbury Winthrop Shaw Pittman LLP acted as legal advisor to Bellicum and Roger Griesmeyer of Hunton Andrews Kurth LLP acted as legal advisor to The University of Texas MD Anderson Cancer Center. The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) on April 15, 2020.공시 • Jul 03Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value IndexBellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index매출 및 비용 세부 내역Bellicum Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:BLCM 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 232-227030 Jun 232-297031 Mar 232-256031 Dec 222-256030 Sep 222-166030 Jun 226-86031 Mar 226-66031 Dec 216-107030 Sep 21679030 Jun 211411031 Mar 211-3713031 Dec 201-816030 Sep 205-5518030 Jun 205-8723031 Mar 207-7027031 Dec 197-11230030 Sep 192-11131030 Jun 193-10229031 Mar 191-10027031 Dec 181-9825030 Sep 181-9323030 Jun 181-9221031 Mar 180-9321031 Dec 170-9221030 Sep 170-9020030 Jun 170-8420031 Mar 170-7619031 Dec 160-6917030 Sep 160-6617030 Jun 160-6216031 Mar 160-5615031 Dec 150-4913030 Sep 150-10611030 Jun 151-978031 Mar 151-906031 Dec 142-854030 Sep 143-143030 Jun 143-123031 Mar 142-103031 Dec 132-920양질의 수익: BLCM 은(는) 현재 수익성이 없습니다.이익 마진 증가: BLCM는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BLCM는 수익성이 없지만 지난 5년 동안 연평균 44.5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BLCM의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BLCM은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BLCM는 현재 수익성이 없으므로 자본 수익률이 음수(-486.06%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/03/05 05:50종가2024/03/04 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bellicum Pharmaceuticals, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Elemer PirosCantor Fitzgerald & Co.Charles ButlerGuggenheim Securities, LLCBiren AminJefferies LLC5명의 분석가 더 보기
Reported Earnings • Apr 01Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
공시 • Mar 31Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020Bellicum Pharmaceuticals, Inc. reported impairment for the fourth quarter ended December 31, 2020. For the quarter, Impairment of property and equipment was $1,265,000.
공시 • Sep 29Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019Bellicum Pharmaceuticals, Inc. announced that they will report Q4, 2018 results at 9:01 PM, GMT Standard Time on Mar 12, 2019
공시 • Mar 04Bellicum Pharmaceuticals Files Form 15Bellicum Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.01 per share.
공시 • Feb 22The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).The University of Texas M. D. Anderson Cancer Center agreed to acquire substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) for $8.1 million on November 21, 2023. Pursuant to the asset purchase agreement, MDACC will pay to Bellicum an amount equal to $8.1 million in cash and will assume certain related liabilities. The transaction is subject to receive approval from Bellicum’s stockholders and certain other customary closing conditions. The asset purchase agreement has been approved by the board of directors of Bellicum and The Board of Regents of the University of Texas System (the “UT Board of Regents”), the governing body for the University of Texas System. Matthew Browne, Rowook Park and Matthew Silverman of Cooley LLP acted as legal advisors to Bellicum Pharmaceuticals. Roger J. Griesmeyer of Katten Muchin Rosenman LLP acted as legal advisors to The University of Texas M.D. Anderson Cancer Center.The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM) on February 21, 2024. As of January 29, 2024, the transaction has been approved by the shareholders of Bellicum Pharmaceuticals.
공시 • Jul 08Nasdaq to Delist the Common Stock of Bellicum PharmaceuticalsNasdaq announced on July 6, 2023 that it will delist the common stock of Bellicum Pharmaceuticals, Inc. The company’s securities were suspended on June 2, 2023, and have not traded on Nasdaq since that time.
공시 • Jun 03Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite IndexBellicum Pharmaceuticals, Inc. has been dropped from NASDAQ Composite Index.
공시 • May 31Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)As previously disclosed by Bellicum Pharmaceuticals, Inc., pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol “BLCM".
Major Estimate Revision • May 21Consensus EPS estimates fall by 39%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.49 to -US$0.68 per share. Revenue forecast of US$8.0k unchanged since last update. Biotechs industry in the US expected to see average net income decline 81% next year. Consensus price target of US$5.00 unchanged from last update. Share price rose 5.8% to US$0.79 over the past week.
공시 • Feb 17Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers SymposiumBellicum Pharmaceuticals, Inc. will present early Phase 1 results for BPX-601 at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco and virtually. The poster titled “Early Results from a Phase 1, Multicenter Trial of PSCA-Specific GoCAR T® Cells (BPX-601) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)” presents initial data from the first two cohorts (n=8) treated with BPX-601. These interim results demonstrated preliminary efficacy of BPX-601 PSCA-directed GoCAR-T cells in combination with rimiducid in heavily pre-treated patients. These initial data from 2 cohorts consisted of 8 patients who received lympodepleting chemotherapy (fludarabine + cyclophosphamide) followed by a single dose of 5x106 BPX-601 cells/kg and single (n=3) or weekly (n=5) doses of 0.4 mg/kg rimiducid beginning 7 days following the cell infusion. GoCAR-T cells are designed to function optimally with repeat dosing of rimiducid to induce the co-activation molecules MyD88 and CD40. The trial continues to enroll patients. The next cohorts in the Phase 1 trial will explore higher doses of rimiducid, which in non-clinical studies have been shown to increase GoCAR-T persistence, enhance pro-inflammatory cytokine production, and improve anti-tumor efficacy.
공시 • Dec 12Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with RimiducidBellicum Pharmaceuticals, Inc. announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial. The poster titled “Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)” will also be available on Bellicum’s website. The UNC Lineberger research team reported the clinical and pharmacodynamic courses of ICANS for four patients treated with rimiducid in an ongoing cell dose expansion cohort of a Phase I/II trial of iC9 CAR.19 cells to treat B-lymphoblastic leukemia (B-ALL). According to the poster, rimiducid administration to these patients experiencing corticosteroid-unresponsive grade 3-4 ICANS was associated with abrupt reduction of circulating iC9 CAR.19 cells and lower ICANS grade within 24 hours. The UNC Lineberger research team concluded that iC9 holds promise as a tool to potentially abrogate the most severe CAR T-cell toxicities. The UNC Lineberger team is exploring lower doses of rimiducid to determine if—by preserving a higher percentage of CAR-T cells—toxicity may be mitigated without diminishing the therapeutic benefit.
Price Target Changed • Nov 16Price target decreased to US$5.00Down from US$17.33, the current price target is provided by 1 analyst. New target price is 367% above last closing price of US$1.07. Stock is down 48% over the past year. The company is forecast to post a net loss per share of US$1.68 next year compared to a net loss per share of US$0.84 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Aug 11Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56Bellicum Pharmaceuticals press release (NASDAQ:BLCM): Q2 GAAP EPS of -$0.13 beats by $0.56. Cash and cash equivalents and restricted cash totaling $34.7M as of June 30, 2022. “We have continued to make progress with our patient enrollment efforts in the BPX-601 and BPX-603 trials and I am pleased with our execution,” said Rick Fair, President and Chief Executive Officer. “Our team remains focused on generating Phase 1 data that highlight the potential advantages of our GoCAR-T technology.”
공시 • May 02Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022, at 13:00 Pacific Standard Time. Agenda: To elect one Class II director named herein to hold office until the 2025 Annual Meeting of Stockholders; to approve an amendment to the Company’s 2019 Equity Incentive Plan to, among other things, increase the number of shares of common stock authorized for issuance under the 2019 Plan by 2,250,000 shares; to ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors to serve as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022; to approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement; and to consider other matters if any.
Price Target Changed • Apr 27Price target decreased to US$5.00Down from US$17.33, the current price target is provided by 1 analyst. New target price is 202% above last closing price of US$1.66. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$2.82 next year compared to a net loss per share of US$0.84 last year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Member of Scientific & Clinical Advisory Board David Spencer was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$1.80, the stock trades at a trailing P/E ratio of 2.3x. Average forward P/E is 8x in the Biotechs industry in the US. Total loss to shareholders of 94% over the past three years.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improved over the past weekAfter last week's 34% share price gain to US$1.90, the stock trades at a trailing P/E ratio of 2.4x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 94% over the past three years.
공시 • Feb 16Bellicum Pharmaceuticals, Inc. Announces Board ChangesOn February 14, 2022, James F. Brown notified Bellicum Pharmaceuticals, Inc. (the “Company”) of his resignation from his position as a member of the Company’s Board of Directors (the “Board”), including each committee of the Board on which he is a member, to be effective as of immediately prior to the Company’s 2022 annual meeting of stockholders. Effective as of Mr. Brown’s resignation, Jon P. Stonehouse will serve as interim Chairman of the Board.
공시 • Dec 15Bellicum Regains Compliance with Nasdaq Continued Listing RequirementsBellicum Pharmaceuticals, Inc. announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the company’s recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to US$1.72, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 27x in the Biotechs industry in the US. Total loss to shareholders of 96% over the past three years.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to US$2.26, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 23x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$3.00, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 25x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years.
Valuation Update With 7 Day Price Move • Aug 24Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$3.32, the stock trades at a trailing P/E ratio of 6.2x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 95% over the past three years.
공시 • May 19Bellicum Pharmaceuticals, Inc. Provides an Operational UpdateBellicum Pharmaceuticals, Inc. provided an operational update. BPX-601 GoCAR-T® •Patient enrollment is ongoing in the Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. •Bellicum plans to present a Phase 1 data update on BPX-601 and rimiducid in patients with metastatic castration-resistant prostate cancer in the first quarter of 2022. BPX-603 GoCAR-T•Bellicum is conducting its Phase 1/2 clinical trial for BPX-603 in patients with solid tumors that express human epidermal growth factor 2 (HER2), including breast, endometrial, ovarian, gastric, and colorectal cancers. BPX-603 is the company’s first dual-switch GoCAR-T product candidate, which incorporates Bellicum’s iMC activation and CaspaCIDe® safety switch technologies. The company expects to present initial Phase 1 data from this trial in the fourth quarter of 2021. CaspaCIDe •As announced in February, the first reported use of the CaspaCIDe safety switch to mitigate CAR-T cell toxicity was published as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. The report described a case from an investigator-sponsored trial at the University of North Carolina Lineberger Comprehensive Cancer Center of autologous CAR-T cells expressing CD19 and CaspaCIDe. In this patient, grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) refractory to standard therapies was treated with rimiducid to activate CaspaCIDe. Within 12 hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days.
Reported Earnings • Apr 01Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)Full year 2020 results: Net loss: US$7.72m (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings.
공시 • Mar 31Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020Bellicum Pharmaceuticals, Inc. reported impairment for the fourth quarter ended December 31, 2020. For the quarter, Impairment of property and equipment was $1,265,000.
공시 • Mar 06Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell ToxicityBellicum Pharmaceuticals, Inc. announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch. The letter to the editor titled “Utility of Safety Switch to Abrogate CD 19 CAR T Cell-Associated Neurotoxicity” appeared as an ahead-of-print publication in the digital edition of Blood, a journal published by The American Society of Hematology. Link to article. The publication detailed a case report from an investigator-sponsored trial (IST) at the University of North Carolina Lineberger Comprehensive Cancer Center, where a Phase 1/2 trial is ongoing to test the safety and efficacy of autologous T lymphocytes genetically modified to express a CD19 chimeric antigen receptor (CAR) and iC9. A patient in the dose expansion cohort of this trial experienced a high grade neurologic adverse event with persistence of grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS) for 72 hours despite standard care, and rimiducid was subsequently given per protocol to activate iC9. Within twelve hours of rimiducid administration, ICANS grade improved from 3 to 1 and was fully resolved after four days. This publication marked the first reported clinical use of the iC9 safety switch to mitigate a severe CAR-T-mediated adverse event refractory to standard of care treatment.
Is New 90 Day High Low • Jan 30New 90-day high: US$4.65The company is up 25% from its price of US$3.71 on 30 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 25% over the same period.
Price Target Changed • Jan 30Price target lowered to US$4.50Down from US$17.33, the current price target is an average from 2 analysts. The new target price is close to the current share price of US$4.65. As of last close, the stock is down 62% over the past year.
공시 • Jan 29Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical TrialBellicum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. Bellicum worked diligently with the FDA over the past two months to respond to the clinical hold and has been informed by FDA that the company has satisfactorily addressed all clinical hold issues. Bellicum may now resume enrollment without modification to the current study protocol. The company plans to work with clinical investigators to resume patient enrollment. About BPX-601: BPX-601, the company’s first GoCAR-T product candidate, incorporates iMC, Bellicum’s inducible co-activation domain. iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence, production of immunomodulatory cytokines and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA).
공시 • Jan 28Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic IndexBellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index
공시 • Jan 12Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021On January 5, 2021, David Strauss notified Bellicum Pharmaceuticals, Inc. of his resignation from his position as the Company’s Senior Director, Corporate Controller, and as the Company’s principal accounting officer, to be effective January 22, 2021.
공시 • Dec 12Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603Bellicum Pharmaceuticals, Inc. announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T® product candidate that incorporates the company’s iMC activation and CaspaCIDe® safety switch technologies. This Phase 1/2, open-label, multicenter, non-randomized study will investigate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid. The trial will enroll patients with previously treated, locally advanced or metastatic solid tumors with HER2 amplification or overexpression. The initial dose escalation phase of the trial is designed to evaluate safety and identify the Phase 2 dose of BPX-603 administered with rimiducid at a fixed dose of 0.4 mg/kg per infusion. The Phase 2 portion of the trial will assess the safety, pharmacodynamics, and clinical activity of BPX-603 in various HER2+ solid tumors. Tumor types that may be studied include gastric, breast, ovarian, endometrial, and colorectal.
공시 • Dec 10Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical TrialBellicum Pharmaceuticals, Inc. announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer. The FDA is taking this action due to the death of a pancreatic cancer patient in the trial reported to the agency by the company. The clinical investigator and Bellicum classified the patient death as unrelated to BPX-601 and rimiducid. The company plans to work diligently with the FDA to address the agency’s questions and fulfill the requirements for resuming the trial. The clinical hold does not affect the company’s plans to initiate enrollment in the Phase 1/2 clinical trial of BPX-603, a dual switch GoCAR-T®, in patients with HER2+ solid tumors by the end of the year.
공시 • Oct 30Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020Bellicum Pharmaceuticals, Inc. staff will be reduced by 79%, from 68 to 14 full-time employees by the end of 2020.
공시 • Sep 29Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019Bellicum Pharmaceuticals, Inc. announced that they will report Q4, 2018 results at 9:01 PM, GMT Standard Time on Mar 12, 2019
공시 • Jul 31The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).The University of Texas MD Anderson Cancer Center entered into an asset purchase agreement to acquire certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) for $15 million on January 17, 2020. The purchase price of $15 million is payable in cash upon closing, less $1.5 million to be held in escrow for up to 18 months after the closing of the transaction. Under the transaction, The University of Texas MD Anderson Cancer Center will acquire approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space. Approximately 35 employees currently employed at the facility will be employed by MD Anderson. The transaction is subject to approval of the Board of Regents of the University of Texas System, the entry into a master services agreement between Bellicum and The University of Texas MD Anderson Cancer Center, completion of an on-site inspection of the facility by certain regulatory entities, Bellicum obtaining consent from the landlord of the facility, and the satisfaction of customary terms and conditions, including adjustment to the purchase price. The transaction is expected to close on or before February 21, 2020. As of March 12, 2020, the closing of the transaction is expected to occur on or before March 31, 2020. Andrew L. Strong of Pillsbury Winthrop Shaw Pittman LLP acted as legal advisor to Bellicum and Roger Griesmeyer of Hunton Andrews Kurth LLP acted as legal advisor to The University of Texas MD Anderson Cancer Center. The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM) on April 15, 2020.
공시 • Jul 03Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value IndexBellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index